Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease

Authors: Martin Wagner, Johannes Krämer, Elisabeth Blohm, Dorothee Vergho, Frank Weidemann, Frank Breunig, Christoph Wanner

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Impairments of health related quality of life (HRQoL) are frequently observed in Fabry disease (FD) and are known to be related to neuropathic pain and cardiovascular events. This study aimed to explore the role of chronic kidney disease (CKD) in a large cohort of patients with FD.

Methods

In 96 patients (53% female; age 40 ± 12 yrs) with genetically proven FD, HRQoL was assessed by the Medical Outcomes Study (SF-36) questionnaire. All patients were naïve to enzyme replacement therapy. Three categories for kidney dysfunction were chosen, eGFR ≥/<60 ml/min/1.73 m2 or need of renal replacement therapy (RRT). Minor (e.g. arrhythmia, angina pectoris, etc.) and major (e.g. myocardial infarction, coronary artery bypass, stroke or implantable cardioverter-defibrillator) vascular events as well as pain and pain therapy were considered in linear regression analyses with the dimensions of HRQoL.

Results

Ten patients (10%) had impaired kidney function and a further nine were on RRT (9.4%). Kidney function and pain emerged as the main factors associated with lower scores on the SF 36, in particular on physical components (PCS beta-coefficients for CKD −6.2, for RRT −11.8, for pain −9.1, p < 0.05, respectively), while controlling for gender, vascular event and pain-therapy. Relationships were found for mental aspects of HRQoL. Age and history of vascular events were not related to HRQoL.

Conclusion

Cardiovascular events and pain are important factors related to HRQoL, social functioning and depression. Our study highlights impaired chronic kidney disease, in particular after initiation of RRT, as a strong determinant of reduced HRQoL in FD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A: Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med. 2010, 12: 668-679. 10.1097/GIM.0b013e3181f13b75.CrossRefPubMed Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A: Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med. 2010, 12: 668-679. 10.1097/GIM.0b013e3181f13b75.CrossRefPubMed
2.
go back to reference Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2010, 8: 539-548.CrossRef Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2010, 8: 539-548.CrossRef
3.
go back to reference Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M: European FOS investigators: natural history of fabry disease in females in the fabry outcome survey. J Med Genet. 2006, 43: 347-352.CrossRefPubMed Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M: European FOS investigators: natural history of fabry disease in females in the fabry outcome survey. J Med Genet. 2006, 43: 347-352.CrossRefPubMed
4.
go back to reference Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP: Fabry registry: females with fabry disease frequently have major organ involvement: lessons from the fabry registry. Mol Genet Metab. 2008, 93: 112-128. 10.1016/j.ymgme.2007.09.013.CrossRefPubMed Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP: Fabry registry: females with fabry disease frequently have major organ involvement: lessons from the fabry registry. Mol Genet Metab. 2008, 93: 112-128. 10.1016/j.ymgme.2007.09.013.CrossRefPubMed
5.
go back to reference Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med. 2001, 345: 9-16. 10.1056/NEJM200107053450102.CrossRefPubMed Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med. 2001, 345: 9-16. 10.1056/NEJM200107053450102.CrossRefPubMed
6.
go back to reference Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007, 18: 1547-1557. 10.1681/ASN.2006080816.CrossRefPubMed Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007, 18: 1547-1557. 10.1681/ASN.2006080816.CrossRefPubMed
7.
go back to reference Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007, 146: 77-86. 10.7326/0003-4819-146-2-200701160-00148.CrossRefPubMed Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007, 146: 77-86. 10.7326/0003-4819-146-2-200701160-00148.CrossRefPubMed
8.
go back to reference Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL: Quality of life of patients with Fabry disease. Qual Life Res. 2002, 11: 317-27. 10.1023/A:1015511908710.CrossRefPubMed Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL: Quality of life of patients with Fabry disease. Qual Life Res. 2002, 11: 317-27. 10.1023/A:1015511908710.CrossRefPubMed
9.
go back to reference Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD: Assessment of health-related quality-of-life in males with Anderson–Fabry disease before therapeutic intervention. Qual Life Res. 2002, 11: 127-33. 10.1023/A:1015009210639.CrossRefPubMed Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD: Assessment of health-related quality-of-life in males with Anderson–Fabry disease before therapeutic intervention. Qual Life Res. 2002, 11: 127-33. 10.1023/A:1015009210639.CrossRefPubMed
10.
go back to reference Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG: Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010, 5: 2220-2228. 10.2215/CJN.04340510.CrossRefPubMedPubMedCentral Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG: Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010, 5: 2220-2228. 10.2215/CJN.04340510.CrossRefPubMedPubMedCentral
11.
go back to reference McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992, 30: 253-265.CrossRef McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992, 30: 253-265.CrossRef
12.
go back to reference Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC: Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2010, 5: 261-267. 10.2215/CJN.03890609.CrossRefPubMedPubMedCentral Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC: Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2010, 5: 261-267. 10.2215/CJN.03890609.CrossRefPubMedPubMedCentral
13.
go back to reference Watt T, Burlina AP, Cazzorla C, Schönfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O’Brien F, Feldt-Rasmussen U: Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010, 12: 703-712. 10.1097/GIM.0b013e3181f13a4a.CrossRefPubMed Watt T, Burlina AP, Cazzorla C, Schönfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O’Brien F, Feldt-Rasmussen U: Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010, 12: 703-712. 10.1097/GIM.0b013e3181f13a4a.CrossRefPubMed
14.
go back to reference Ware J, Kosinski M, Keller SK: SF-36 Physical and Mental Health Summary Scales, A User’s Manual. 1994, Booston, MA: The Health Institute Ware J, Kosinski M, Keller SK: SF-36 Physical and Mental Health Summary Scales, A User’s Manual. 1994, Booston, MA: The Health Institute
15.
go back to reference National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-S266. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-S266.
16.
go back to reference MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001, 38: 750-60. 10.1136/jmg.38.11.750.CrossRefPubMedPubMedCentral MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001, 38: 750-60. 10.1136/jmg.38.11.750.CrossRefPubMedPubMedCentral
17.
go back to reference Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T: Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007, 61: 293-302. 10.1111/j.1742-1241.2006.01237.x.CrossRefPubMed Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T: Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007, 61: 293-302. 10.1111/j.1742-1241.2006.01237.x.CrossRefPubMed
18.
go back to reference Grewal RP: Psychiatric disorders in patients with Fabry’s disease. Int J Psychiatry Med. 1993, 23: 307-12. 10.2190/JKFW-3WXK-QA7N-BYLN.CrossRefPubMed Grewal RP: Psychiatric disorders in patients with Fabry’s disease. Int J Psychiatry Med. 1993, 23: 307-12. 10.2190/JKFW-3WXK-QA7N-BYLN.CrossRefPubMed
19.
go back to reference Hoffmann B: Effects of enzyme replacement therapy on pain and overall quality of life. Fabry Disease: Perspectives from 5 Years of FOS. Edited by: Mehta A, Beck M, Sunder-Plassmann G. 2006, Oxford: Oxford PharmaGenesis, Chapter 40 Hoffmann B: Effects of enzyme replacement therapy on pain and overall quality of life. Fabry Disease: Perspectives from 5 Years of FOS. Edited by: Mehta A, Beck M, Sunder-Plassmann G. 2006, Oxford: Oxford PharmaGenesis, Chapter 40
20.
go back to reference Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003, 28: 703-10. 10.1002/mus.10497.CrossRefPubMed Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003, 28: 703-10. 10.1002/mus.10497.CrossRefPubMed
21.
go back to reference Beck M, Ricci R, Widmer U, Dehout F, De Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A: Fabry disease: overall effects of agalsidase alfa treatment. Eur J ClinInvest. 2004, 34: 838-844. 10.1111/j.1365-2362.2004.01424.x.CrossRef Beck M, Ricci R, Widmer U, Dehout F, De Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A: Fabry disease: overall effects of agalsidase alfa treatment. Eur J ClinInvest. 2004, 34: 838-844. 10.1111/j.1365-2362.2004.01424.x.CrossRef
22.
go back to reference Hoffmann B, Garcia De Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005, 42: 247-252. 10.1136/jmg.2004.025791.CrossRefPubMedPubMedCentral Hoffmann B, Garcia De Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005, 42: 247-252. 10.1136/jmg.2004.025791.CrossRefPubMedPubMedCentral
23.
go back to reference Zarate YA, Hopkin RJ: Fabry’s disease. Lancet. 2008, 372: 1427-1435. 10.1016/S0140-6736(08)61589-5.CrossRefPubMed Zarate YA, Hopkin RJ: Fabry’s disease. Lancet. 2008, 372: 1427-1435. 10.1016/S0140-6736(08)61589-5.CrossRefPubMed
24.
go back to reference Angst F, Aeschlimann A, Stucki G: Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001, 45: 384-391. 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0.CrossRefPubMed Angst F, Aeschlimann A, Stucki G: Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001, 45: 384-391. 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0.CrossRefPubMed
25.
go back to reference Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML: CFDI investigators. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014, 111: 499-506. 10.1016/j.ymgme.2014.01.014.CrossRefPubMed Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML: CFDI investigators. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014, 111: 499-506. 10.1016/j.ymgme.2014.01.014.CrossRefPubMed
26.
go back to reference Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M: Fabry disease in children and response to enzyme replacement therapy: results from FOS – the Fabry Outcome Survey. Clinical Genetics. 2012, 81: 485-90. 10.1111/j.1399-0004.2011.01671.x.CrossRefPubMed Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M: Fabry disease in children and response to enzyme replacement therapy: results from FOS – the Fabry Outcome Survey. Clinical Genetics. 2012, 81: 485-90. 10.1111/j.1399-0004.2011.01671.x.CrossRefPubMed
Metadata
Title
Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease
Authors
Martin Wagner
Johannes Krämer
Elisabeth Blohm
Dorothee Vergho
Frank Weidemann
Frank Breunig
Christoph Wanner
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-188

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.